Article | June 4, 2024

Point-Of-Care Manufacturing vs. Decentralized Manufacturing In Cell & Gene Therapies

Source: Germfree

By Stephen Ondek, Customer-Focused Cleanroom Professional


Point-of-Care (PoC) and Decentralized Manufacturing are the two most prominent production models used in cell and gene therapies. PoC Manufacturing involves producing therapies on-site, enhancing the speed and personalization of treatment delivery by producing therapies where patients receive treatment. However, this requires a significant investment in specialized equipment, training, and regulatory compliance. On the other hand, Decentralized Manufacturing increases accessibility and scalability by spreading production across multiple units in different locations, with its own challenges of robust coordination, quality control, and resource allocation. The specific needs and capabilities of your organization, along with the patient population, can help determine which of these two models will best suit your needs.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online